β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features

Abstract Background The emergence of de novo or intrinsic trastuzumab resistance is exceedingly high in breast cancer that is HER2 positive and correlates with an abundant cancer stem cell (CSC)-like population. We sought to examine the capacity of β-escin, an anti-inflammatory drug, to address tras...

Full description

Bibliographic Details
Main Authors: Soeun Park, Jung Min Park, Minsu Park, Dongmi Ko, Seongjae Kim, Juyeon Seo, Kee Dal Nam, Eunsun Jung, Lee Farrand, Yoon-Jae Kim, Ji Young Kim, Jae Hong Seo
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Cancer Cell International
Subjects:
β-escin
Trastuzumab resistance
Drug repurposing
p95HER2
HER2-positive breast cancer
Cancer stem cells
Online Access:https://doi.org/10.1186/s12935-022-02713-9

Internet

https://doi.org/10.1186/s12935-022-02713-9

Similar Items